Last updated: May 28, 2025
Sponsor: Tor Biering-Sørensen
Overall Status: Active - Not Recruiting
Phase
4
Condition
Respiratory Syncytial Virus (Rsv) Infection
Respiratory Syncytial Virus (Rsv)
Treatment
RSV prefusion F protein-based vaccine
Clinical Study ID
NCT06684743
DAN-RSV
2024-516600-42-00
Ages > 60 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Age 60 years and above
Informed consent form has been signed and dated
Exclusion
Exclusion Criteria:
- There are no specific exclusion criteria for this study
Study Design
Total Participants: 130000
Treatment Group(s): 1
Primary Treatment: RSV prefusion F protein-based vaccine
Phase: 4
Study Start date:
November 18, 2024
Estimated Completion Date:
August 31, 2027
Study Description
Connect with a study center
Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
Copenhagen, 2900
DenmarkSite Not Available
Danske Lægers Vaccinations Service
Søborg, 2860
DenmarkSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.